Old Web
English
Sign In
Acemap
>
Paper
>
109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
2021
Maurice Pérol
Thomas Filleron
Xavier Quantin
Christos Chouaïd
C Audigier Valette
Hervé Léna
Coureche Kaderbhai
C. Fabre
M Santorelli
L. Bensimon
T. Burke
D. Couch
E Nguyen
C. Courtinard
Keywords:
Oncology
Internal medicine
PD-L1 Positive
Pembrolizumab
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]